Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion

Excess mineralocorticoid receptor (MR) activation promotes target organ dysfunction, vascular injury and fibrosis. MR antagonists like eplerenone are used for treating heart failure, but their use is limited due to the compound class-inherent hyperkalemia risk. Here we present evidence that AZD9977,...

Full description

Saved in:

Bibliographic Details
Published in:	PLoS One
Main Authors:	Bamberg, Krister, Johansson, Ulrika, Edman, Karl, William-Olsson, Lena, Myhre, Susanna, Gunnarsson, Anders, Geschwindner, Stefan, Aagaard, Anna, Björnson Granqvist, Anna, Jaisser, Frédéric, Huang, Yufeng, Granberg, Kenneth L., Jansson-Löfmark, Rasmus, Hartleib-Geschwindner, Judith
Format:	Artigo
Language:	Inglês
Published:	Public Library of Science 2018
Subjects:	Research Article
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5825103/ https://ncbi.nlm.nih.gov/pubmed/29474466 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0193380
Tags:	Add Tag No Tags, Be the first to tag this record!

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion

Similar Items